抗体部会
抗体薬物複合体5月3日〜4日
臨床開発の後期段階にある抗体薬物複合体(ADC)は、充実性腫瘍と血液系腫瘍の両方に対して有望な治療効果を示しています。特異性、効能、リンカー技術、複合体部位設計、医薬品の化学量と配列といったパラメーターが最適化されたことにより、ADCは大きな進化を遂げているのです。この学会では、次世代ADCの設計と発見、成功裏に開発が進む臨床候補から得られた最新の知識を生かす方法などが紹介されることになっています。
1日目 | 2日目
5月3日, 木曜日
12:00 pm Registration
1:30 Chairperson's Opening Remarks
Pamela A. Trail, Ph.D., Vice President, Oncology, Regeneron Pharmaceuticals, Inc.
» 1:40 Featured Speaker
Lessons Learned from the Clinic – T-DM1 and Beyond
John Lambert, Ph.D., CSO, ImmunoGen, Inc.
Since 1999, a number of antibody-maytansinoid conjugates (AMCs) have entered clinical testing, with the most advanced of these, T-DM1 and SAR3419, attracting attention for their efficacy and tolerability profile. Lessons learned from earlier AMCs helped inform the design of these compounds, and this body of knowledge that can be applied to AMC design continues to expand and will be discussed.
|
» 2:10 Featured Speaker
The Development of ADCs at Seattle Genetics
Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine, Seattle Genetics
Antibody-drug conjugates (ADCs) represent an important class of new cancer therapeutics under development. The deceptively simple concept of targeted drug delivery has been an elusive goal for decades but has been realized with the approval of brentuximab vedotin (ADCETRIS).The current approach to designing empowered antibodies and testing them both pre-clinically and clinically will be discussed.
|
2:40 Sponsored Presentations (Opportunities Available)
3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Clinical Case Study
Anne Bousseau, M.D., Head, Early Development Projects, Global Oncology, Sanofi-Aventis
4:30 Antibody-Drug Conjugates: Pre-Clinical Evaluation of a Novel Target
Andrew Simmons, Ph.D., Associate Director, Oncology, Takeda California
5:30-8:30 pm Recommended Dinner Short Course*
SC14 Antibody Conjugate Therapeutics: Potential and Challenges
*Separate registration required.
|
1日目 | 2日目
.jpg "Pharma-Bio Partnsering Forum")